Unlike commercial and Medicaid plans, Medicare Part D plans favor high list-price drugs when identical low list-price drugs are available, according to Drug Channels CEO Adam Fein, who analyzed newly released data from IQVIA on market share of hepatitis C drugs.
NON-SUBSCRIBER OPTIONS
FREE TRIAL | NEWSSTAND
Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.
Log in to access this content.
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.
© 2002-2020. Inside Washington Publishers | Contact Us